Hoth Therapeutics announces issuance of Chinese patent for cancer cell-targeting technology
The technology selectively shuts down cancer reproducing cells
10 Apr 2026
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, has announced that the China National Intellectual Property Administration (CNIPA) has granted a Chinese Patent, titled 'Targeting Kit with Splice Switching Oligonucleotides to Induce Apoptosis of Mast Cells.'
The patent relates to a novel therapeutic platform utilizing splice-switching oligonucleotides designed to selectively induce apoptosis in mast cells, which play a central role in a variety of inflammatory and immunological conditions. The patent, originally filed under PCT Application No. PCT/US2019/048400 and developed by North Carolina State University, strengthens Hoth's intellectual property portfolio.
"This patent grant in China represents an important milestone in expanding our global intellectual property protection for this innovative platform," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "We believe this technology has broad potential across multiple indications where mast cell activity contributes to disease, and this issuance further strengthens our position as we advance development."